Partner With Us NRI

Sun Pharmaceuticals Industries Ltd share Price Today

Company details

6M Return 22.94%
1Y Return 53.43%
Mkt Cap.(Cr) 363,739.19
Volume 937,490
Div Yield 0.89%
OI Chg %
Volume 937,490

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Sun Pharmaceutical Industries announced Q3FY24 & 9MFY24 results:

  • Consolidated Q3FY24:
    • Gross sales at Rs 121,569 million, growth of 9.5%
    • India formulation sales at Rs 37,785 million, up 11.4%
    • US formulation sales at US$ 477 million, up 13.2%
    • Global specialty sales at US$ 296 million, including US$20 million milestone received in Q3. Ex-milestones, up 24.2%
    • Global specialty sales, ex-milestone, accounted for 19.2% of Q3FY24 sales
    • Emerging Markets formulation sales at US$ 252 million, lower by 2.3%
    • Rest of World formulation sales at US$ 214 million, up 12.9%
    • R&D investments at Rs 8,245 million compared to Rs 6,702 million for Q3FY23
    • EBITDA at Rs 34,768 million (including other operating revenues), up 15.8%. EBITDA margin for Q3 at 28.1% vs 26.7% during Q3FY23
    • Adjusted net profit (excluding the exceptional items) for Q3FY24 was Rs 25,936 million, up 19.7%. Reported net profit for Q3FY24 was Rs 25,238 million compared to Rs 21,660 mn during Q3FY23
  • Consolidated 9MFY24:
    • Gross sales at Rs 359,451 million, growth of 10.4%
    • India formulation sales at Rs 111,814 million, up 9.2%
    • US formulation sales at US$ 1,378 million up 9.8%
    • Emerging Markets formulation sales at US$ 796 million, up 4.5%
    • Rest of World formulation sales at US$ 615 million, up 9.7%
    • EBITDA at Rs 99,880 million (including other operating revenues), up 12.9%, with a resulting EBITDA margin of 27.4%
    • Net profit for 9MFY24 was Rs 69,218 million. Like for like, adjusted net profit at Rs 73,145 million, up 12.7%
  • The Board has declared an interim dividend of Rs 8.50 per share for the year FY24 against Rs 7.50 per share interim dividend for the previous year. 

Result PDF

View Other Company Results

Sun Pharmaceuticals Industries Ltd shares SWOT Analysis

Strengths (12)

  • Rising Net Cash Flow and Cash from Operating activity
  • Company with high TTM EPS Growth
  • Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Weakness (1)

  • MFs decreased their shareholding last quarter

Opportunity (0)

Data not found

Threats (2)

  • Red Flags: Firms linked to ongoing regulatory investigations/legal cases
  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,520.8
R2 1,525.6
R3 1,533.3


S1 1,508.4
S2 1,500.7
S3 1,495.9
Delivery and volume
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Purchase 2024-02-27 1556.95 656286 BSE
SOCIETE GENERALE Block Purchase 2024-01-25 1382.1 3253896 BSE
Name Category Shares
Dilip. S. Shanghvi PROMOTER 9.6%
Sudhir V. Valia PROMOTER 0.6%
Shanghvi Finance Private Limited PROMOTER 40.3%
Aditya Medisales Limited PROMOTER 1.67%
Raksha S.Valia PROMOTER 1.2%


Investment recommendation
Decent quarter; cautious guidance…
Call Date
23 May 2024
Entry Price 1,480.00
Target Price 1,530.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Sun Pharmaceuticals Industries Ltd Stocks COMPARISON

Financials( in Cr) Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd Dr Reddys Laboratories Ltd
Price 1,516.00 1,564.75 4,588.60 1,109.55 6,085.25
% Change 0.34 1.31 -0.11 1.75 -0.17
Mcap Cr 363,739.19 126,332.75 121,813.11 111,646.69 101,512.92
Revenue TTM Cr 43,885.68 15,790.60 7,767.51 17,237.40 24,669.70
Net Profit TTM Cr 8,560.84 2,513.47 1,823.38 1,997.30 4,507.30
PE TTM 36.34 29.68 76.10 28.94 18.20
1 Year Return 53.43 59.42 31.57 114.34 29.42
ROCE 16.79 14.76 19.30 16.25 25.99
ROE 16.46 10.66 14.89 14.05 21.21

Equity Capital: 55,995.38 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 33,119.99 -408.46
LAST 3M 113,155.52 -36,230.77
LAST 6M 183,603.09 -15,050.11
LAST 12M 290,144.87 98,834.05
Sun Pharmaceutical Industries Limited - Press Release

Jun 14, 2024 l NSE Announcement

Sun Pharmaceutical Industries Limited - Updates

Jun 12, 2024 l NSE Announcement

Sun Pharmaceutical Industries Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 11, 2024 l NSE Announcement

Date Action Type Ratio
Feb 09, 2024 Dividend 850
Jul 28, 2023 Dividend 400
Feb 08, 2023 Dividend 750

Sun Pharmaceuticals Industries Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Sun Pharmaceuticals Industries Ltd. is the fourth-largest speciality generic pharmaceutical company in the world. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries worldwide. The company was founded in 1983 with its headquarters in Mumbai. For the quarter ended June 2022, Sun Pharmaceuticals Industries Ltd.’s total income was Rs HYPERLINK "https://economictimes.indiatimes.com/sun-pharmaceutical-industries-ltd/stocks/companyid-9134.cms" 10,763.90 crore, up 12.59% from the previous financial year. On 5 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sunpharmaceuticalindustries/SPI" 219,767 crore.  

    Sun Pharmaceuticals Industries Ltd. is listed on the Bombay Stock Exchange with the code 524715. It is listed on the National Stock Exchange with the code SUNPHARMA. It is also listed on the MCX Stock Exchange. 

    Sun Pharmaceuticals Industries Ltd. has more than 40 manufacturing facilities. Its product portfolio consists of generics, branded generics, over-the-counter (OTC), difficult-to-make technology-intensive products, antiretrovirals (ARVs), speciality, Active Pharmaceutical Ingredients, and its intermediates. A few flagship OTC brands of the company include Revital, Volini, and Faringosept. 

    As of 30 June 2022, the company’s shareholding pattern indicated a promoter stake of 54.48%, foreign institutional investor stake of 14.95%, domestic institutional investor stake of 19.67%, and public stake of 10.91%. During the quarter ended June 2022, promoters unpledged 1.53% of shares, making the total promoter pledge stand at 4.04%. The mutual fund holdings increased from 11.63% to 11.84%, while the promoter’s holding remained unchanged. The total shares outstanding were 239.93 crores.  

    The company’s chairman is Mr Israel Makov. The founder and managing director isMr Dilip Sanghvi. The North American CEO is Mr Abhay Gandhi. Ms Kirti Ganorkar is the India CEO. The other members of the top management comprise Mr Anilkumar Jain, Mr Kalyanasundaram Subramanian, Mr Sudhir V Valia, Dr Pawan Goenka, Mr Rama Bijapurkar, and Mr Gautam Doshi, among others. The auditors are SRBC & Co. LLP.  

    On 5 August 2022, the share price of Sun Pharmaceuticals Industries Ltd. closed at Rs 916.35 on BSE and at Rs 915.95 on NSE. The 52-week high for Sun Pharmaceuticals Industries Ltd.’s share price was Rs 967.05, and the 52-week low for the company’s share price was Rs 733.70. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Sun Pharma Advanced Res.Centre, Tandalja, Vadodara, Gujarat, 390020

Tel : 91-265-6615500
Email : secretarial:sunpharma.com
Website : http://www.sunpharma.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524715
Book Closure Date (Month) :
BSE Group : A
ISIN : INE044A01036

FAQ’s on Sun Pharmaceuticals Industries Ltd Shares

You can buy Sun Pharmaceuticals Industries Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sun Pharmaceuticals Industries Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:58 PM the closing price of Sun Pharmaceuticals Industries Ltd was Rs.1,516.00.

The latest PE ratio of Sun Pharmaceuticals Industries Ltd as of Jun 14, 2024 03:58 PM is 36.34

The latest PB ratio of Sun Pharmaceuticals Industries Ltd as of Jun 14, 2024 03:58 PM is 0.18

The 52-week high of Sun Pharmaceuticals Industries Ltd share price is Rs. 1,638.85 while the 52-week low is Rs. 977.30

According to analyst recommendations, Sun Pharmaceuticals Industries Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:58 PM, the market cap of Sun Pharmaceuticals Industries Ltd stood at Rs. 363,739.19.

Download App

Download Our App

Play Store App Store
market app